Literature DB >> 19383496

Methotrexate induces apoptosis in CaSki and NRK cells and influences the organization of their actin cytoskeleton.

Antonina Joanna Mazur1, Dorota Nowak, Hans Georg Mannherz, Maria Malicka-Błaszkiewicz.   

Abstract

Methotrexate is a widely used drug in treatments of various types of malignancies and in the therapy of rheumatoid arthritis. The goal of our study was to look at the effect of this dihydrofolate reductase inhibitor on the actin cytoskeleton, since actin plays an important role in cancer transformation and metastasis. For this reason we compared results obtained from experiments on CaSki (human uterine cervix cancer) and NRK (normal fibroblastic rat kidney) cells treated with methotrexate. It has been shown previously that methotrexate can induce apoptosis. Therefore we first examined whether methotrexate induces apoptosis in our model cells. For this aim we applied several assays like Caspase Glo 3/7, DNA fragmentation and binding of phosphatidylserine by annexin V-fluorescein. The data obtained indicated that methotrexate induces programmed cell death in CaSki and NRK cells. However, differences between CaSki and NRK cells were observed in the morphological alterations and dynamics of apoptosis induced by methotrexate. It seemed that cancer cells were more sensitive towards the cell death inducing activity at lower concentrations of methotrexate. Analysis by confocal microscopy of methotrexate-treated cells demonstrated that treatment with this folate antagonist affected the actin cytoskeleton, although the dis-organization of the actin cytoskeleton after treatment with methotrexate differed between cancer and normal cells.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19383496     DOI: 10.1016/j.ejphar.2009.04.020

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  7 in total

1.  Relationship between membrane permeability and specificity of human secretory phospholipase A(2) isoforms during cell death.

Authors:  Jennifer Nelson; Elizabeth Gibbons; Katalyn R Pickett; Michael Streeter; Ashley O Warcup; Celestine H-Y Yeung; Allan M Judd; John D Bell
Journal:  Biochim Biophys Acta       Date:  2011-04-12

2.  Expression and functional role of HLA-G in immune cells from patients with systemic lupus erythematosus.

Authors:  Adriana Elizabeth Monsiváis-Urenda; Lourdes Baranda; Crisol Alvarez-Quiroga; Carlos Abud-Mendoza; Roberto González-Amaro
Journal:  J Clin Immunol       Date:  2010-12-29       Impact factor: 8.317

3.  The protective effects of Prunus armeniaca L (apricot) against methotrexate-induced oxidative damage and apoptosis in rat kidney.

Authors:  Nigar Vardi; Hakan Parlakpinar; Burhan Ates; Asli Cetin; Ali Otlu
Journal:  J Physiol Biochem       Date:  2012-11-10       Impact factor: 4.158

4.  Beneficial effects of Chrysin against Methotrexate-induced hepatotoxicity via attenuation of oxidative stress and apoptosis.

Authors:  Nemat Ali; Summya Rashid; Sana Nafees; Syed Kazim Hasan; Sarwat Sultana
Journal:  Mol Cell Biochem       Date:  2013-10-24       Impact factor: 3.396

5.  In vitro evaluation of combination of EGCG and Erlotinib with classical chemotherapeutics on JAR cells.

Authors:  Elçin Telli; Hatice Genç; Burcugül Altuğ Tasa; S Sinan Özalp; A Tansu Koparal
Journal:  In Vitro Cell Dev Biol Anim       Date:  2017-05-01       Impact factor: 2.416

6.  Combined antitumoral effects of pretubulysin and methotrexate.

Authors:  Sarah Kern; Ines Truebenbach; Miriam Höhn; Jan Gorges; Uli Kazmaier; Stefan Zahler; Angelika M Vollmar; Ernst Wagner
Journal:  Pharmacol Res Perspect       Date:  2019-01-22

7.  Alleviation of Liver Dysfunction, Oxidative Stress and Inflammation Underlies the Protective Effect of Ferulic Acid in Methotrexate-Induced Hepatotoxicity.

Authors:  Mozhdeh Roghani; Heibatullah Kalantari; Mohammad Javad Khodayar; Layasadat Khorsandi; Mojtaba Kalantar; Mehdi Goudarzi; Hadi Kalantar
Journal:  Drug Des Devel Ther       Date:  2020-05-20       Impact factor: 4.162

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.